top of page

MAPS Israel, Psychedelic Invest and Neuly Present Virtual Webinar: Healing Using MDMA for PTSD in Israel



MAPS Israel, Psychedelic Invest and Neuly invite the community to its free, live virtual panel, “Healing October 7th: Using MDMA for PTSD in Israel” on Tuesday, Jan. 30 at 11 a.m. ET. Moderated by Iter Investments’ Managing Principal Dustin Robinson, Esq. CPA, speakers will include MAPS Israel CEO Keren Tzarfaty, Ph.D., and Entrepreneur in Residence at MAPS Israel, Eyal Gura. The virtual panel will discuss MAPS Israel’s initiative to address the Oct. 7 attack in Israel and how MDMA can have healing powers for those who have been affected in Israel.


 

Tzarfaty is the co-founder and CEO of MAPS Israel and leads psychedelic-assisted studies in Israel. She is a senior trainer and supervisor for MPBC and has been a clinical investigator in MPBC MDMA-assisted psychotherapy FDA-approved clinical studies. Tzarfaty is the co-founder of the Hakomi Institute of Israel, a Hakomi Trainer and one of the founders of the new MA program at Haifa University: Integrative Psychotherapy: Body, Mind, spirit. She holds an MA in Somatic Psychology and a Ph.D. in East-West Psychology.

 

Gura is the co-founder and chairman of Zebra Medical Vision, a deep-learning medical imaging company that will enable scalable healthcare for the two billion people to join the middle class by 2025. Gura is currently the Entrepreneur in Residence at MAPS Israel and a venture investor. Gura is an Angel investor and previously venture capitalist with Pitango Venture Capital, the largest venture capital fund in the Middle East. He is a faculty member at IDC’s Zell entrepreneurship program and a graduate of the Wharton Business School of the University of Pennsylvania.

 

Robinson is the managing principal of psychedelics venture capital firm Iter Investments; founding partner of psychedelics and cannabis law firm Mr. Cannabis Law; co-founder of psychedelics non-profit Mr. Psychedelic Law; and co-founder of psychedelics data ecosystem Nucleus. He is a leader within the psychedelic ecosystem and has been ranked by Psychedelic Invest as the Top 100 Most Influential People in Psychedelics. Robinson is an expert in navigating and capitalizing on opportunities within highly regulated industries and is the co-founder of a non-profit that is paving the way for psychedelic legalization.

 

To continue to raise awareness surrounding the attack in Israel and to raise money for MAPS Israel – a nonprofit that is doing clinical trials for MDMA for PTSD in Israel – the team will also host an in-person panel at Soho Beach House Miami featuring Rick Doblin on Thursday, Feb. 29 at 7 p.m. and a Shabbat dinner fundraiser on Friday, March 1 at a private, undisclosed location in Miami Beach. More details on the location of the event will be provided upon RSVP. If interested in attending the March 1 Shabbat dinner, please email iter@dureeandcompany.com.

 

When:

Tuesday, January 30; 11 a.m. ET

 

Where/How:

The event is a live virtual panel that is open to the public. To reserve a spot, please visit the following link: https://psychedelicinvest.com/webinar-healing-october-7th-using-mdma-for-ptsd-in-israel-presented-by-maps-israel/

 

Cost: Free

 

About MAPS Israel


MAPS Israel is an Israeli non-profit organization whose mission is to develop psychedelic research and educational programs based in public health, informed by medical, cultural and legal knowledge. MAPS Israel focuses on promoting and supporting new, groundbreaking treatments for post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), eating disorders, and other medical indications. For more information, visit https://www.maps-israel.org/.

 

About Psychedelic Invest


Psychedelic Invest is a resource equipping investors with reports and insights spanning the growing industry of plant, entheogenic and psychoactive medicines. For more information, visit www.psychedelicinvest.com.

 

About Neuly


Neuly is a leading psychedelics data platform that provides researchers and drug developers with access to a comprehensive dataset of psychedelics research. Neuly’s platform includes a variety of features to help researchers and drug developers save time and improve the efficiency of their work. For more information visit www.neuly.com.


By ML Staff. Top image by Jakub Matyáš/unsplash

Comments


bottom of page